Eli Lilly reported first-quarter earnings and revenue that exceeded Wall Street expectations on Thursday and raised its full-year sales outlook by $2 billion, driven by strong demand for its obesity and diabetes treatments Zepbound and Mounjaro.
Some Chinese pharmaceutical companies are shifting focus to producing generic versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound as U.S. demand for makeshift weight-loss drugs slows. Over the past two years, Chinese suppliers provided raw ingredients for more than a billion doses sold online by compounding pharmacies, fueled by telehealth services.
30 Apr 2026-15:51
02 Sep 2025-16:53
